子宫肌瘤射频热消融:长期临床结局与再干预
回顾性随访队列研究纳入2007年11月1日至2010年2月26日连续66例子宫肌瘤患者,行超声引导射频热消融后长期随访。症状严重度评分从基线57.2±16.6降至长期随访23.8±20.8(p<.001)。22例(35%)接受重大再干预,肌瘤相关症状的重大再干预率2年为13.5%、5年为29.1%。
要点
- 症状严重度评分从基线57.2±16.6持续改善至长期随访23.8±20.8(p<.001)。
- 22例(35%)接受重大再干预,其中15例子宫切除、7例子宫肌瘤剔除。
- 肌瘤相关症状的重大再干预率2年为13.5%(95%CI 7%-25%),5年为29.1%(95%CI 19%-43%)。
核心结论
- 超声引导射频热消融是子宫肌瘤的一种替代治疗选择,尤其适用于≥45岁且仅有1个肌瘤(体积≤180 cm3)的女性,并需要进一步评估。
研究设计与样本
- 回顾性随访队列研究(加拿大任务组分类II-2),纳入2007年11月1日至2010年2月26日连续66例子宫肌瘤女性,平均年龄45±7岁,肌瘤为国际妇产科联盟2至5型,中位体积122.5 cm3(范围24-675)。
主要发现
- 62例中40例接受随访且未行或仅行轻微宫腔镜再干预,其中35例完成UFS-QOL问卷,症状严重度评分(100分制)从基线57.2±16.6改善至长期随访23.8±20.8(p<.001)。
- 22例(35%)接受重大再干预,包括15例子宫切除和7例子宫肌瘤剔除,其中6例因非肌瘤相关原因接受重大再干预。
- Kaplan-Meier法估计肌瘤相关症状的重大再干预率2年为13.5%(95%CI 7%-25%),5年为29.1%(95%CI 19%-43%)。
- ≥45岁女性重大再干预率2年为12%(95%CI 5%-26%)、5年为19%(95%CI 10%-35%),<45岁女性分别为35.0%(95%CI 19%-60%)和73.8%(95%CI 52%-92%)。
- 仅1个射频消融肌瘤(体积≤180 cm3,直径<7 cm)的女性重大再干预少于多于1个射频消融肌瘤(>180 cm3)的女性(p<.01),前者2年和5年再干预率分别为13%(95%CI 6%-28%)和26%(95%CI 14%-45%)。
临床怎么用
- 作者认为超声引导射频热消融是子宫肌瘤的一种替代治疗选择,尤其适用于≥45岁且仅有1个肌瘤(体积≤180 cm3)的女性,并需要进一步评估。
局限性
- 原文结论指出该治疗需要进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To assess the long-term efficacy and rate of reintervention after ultrasound-guided radiofrequency thermal ablation (RFA) for uterine myomas. DESIGN: A retrospective follow-up, cohort study (Canadian Task Force classification II-2). SETTING: University hospitals and private clinics. PATIENTS: Between November 1, 2007, and February 26, 2010, 66 consecutive women underwent ultrasound-guided RFA. INTERVENTIONS: Patients underwent abdominal or vaginal ultrasound-guided RFA and were contacted for a long-term follow-up to complete the Uterine Fibroid Symptom and Quality of Life Score (UFS-QOL) questionnaire and optional ultrasound and examination. MEASUREMENTS AND MAIN RESULTS: Sixty-six consecutive patients (mean age 45 ± 7 years) with type 2 to 5 symptomatic myomas per the International Federation of Gynecology and Obstetrics (median size = 122.5 cm3 [range, 24-675]) were included. Forty of 62 patients recruited for follow-up underwent no/minor hysteroscopic reinterventions; 35 patients from this group completed the UFS-QOL questionnaire and showed sustained and improved symptom severity scores (100-point scale) from baseline (57.2 ± 16.6) to long-term follow-up (23.8 ± 20.8, p < .001). Twenty-two patients (35%) had major reinterventions (15 hysterectomies and 7 myomectomies). Six of the 22 patients underwent major reinterventions for reasons other than myoma-related complaints. The estimated major reintervention rate because of myoma-related symptoms determined by the Kaplan-Meier method was 13.5% (95% confidence interval [CI], 7%-25%) after 2 years and 29.1% (95% CI, 19%-43%) after 5 years. Women ≥45 years of age had a major reintervention rate of 12% (95% CI, 5%-26%) after 2 years and 19% (95% CI, 10%-35%) after 5 years, and women <45 years had a major reintervention rate of 35.0% (95% CI, 19%-60%) and 73.8% (95% CI, 52%-92%) after 2 and 5 years, respectively. Fewer major reinterventions occurred in women with only 1 RFA-treated myoma (volume ≤180 cm3, diameter <7 cm) than women with more than 1 RFA-treated myoma (>180 cm3, p < .01). The Kaplan-Meier estimates for reintervention in women with only 1 RFA-treated myoma with a volume ≤180 cm3 were 13% (95% CI, 6-28%) and 26% (95% CI, 14%-45%) after 2 and 5 years, respectively. No patients with morphologic myoma characteristics underwent reinterventions. CONCLUSION: Ultrasound-guided RFA for uterine myomas is an alternative treatment option especially for women ≥45 years of age with only 1 myoma (volume ≤180 cm3) and warrants further evaluation.
引用
- Iversen H, Dueholm M. Radiofrequency Thermal Ablation for Uterine Myomas: Long-term Clinical Outcomes and Reinterventions. J Minim Invasive Gynecol. 2017. PMID: 28662989. doi:10.1016/j.jmig.2017.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。